Tutorials › Pharmacometrics › First-Pass Metabolism in PBPK
Pharmacokinetics · PBPK Foundations

First-Pass Metabolism in PBPK

Understand how orally administered drugs can be metabolized in the intestine and liver before reaching the systemic circulation—and how physiologically based pharmacokinetic models represent these processes mechanistically.

Intermediate PBPK Drug Metabolism Clinical Pharmacology
01 · The big picture

1. What Is First-Pass Metabolism?

First-pass metabolism refers to the metabolism of a drug after administration at an absorptive site but before the drug reaches the systemic circulation. For an orally administered drug, the most important sites are often the intestinal wall and liver.

After an oral dose, drug may dissolve in the gastrointestinal tract, cross the intestinal epithelium, enter the portal circulation, pass through the liver, and only then reach the systemic circulation. Drug can be metabolized at several of these steps.

Oral dose GI lumen Intestine absorption transport metabolism portal blood Liver hepatic uptake metabolism systemic release systemic circulation First-pass loss can occur before drug reaches systemic circulation.

For many oral drugs, intestinal and hepatic processes contribute to the fraction of the administered dose that ultimately reaches systemic circulation.

Core idea: first-pass metabolism is not simply a single “liver effect.” In a mechanistic PBPK model, presystemic loss can arise from intestinal metabolism, hepatic metabolism, transport, blood flow, and other processes that determine how much drug survives the journey to the systemic circulation.
02 · Oral disposition

2. What Happens After an Oral Dose?

An oral dose does not enter the systemic circulation as a single instantaneous event. Instead, several processes occur sequentially and sometimes simultaneously.

  1. Dissolution: drug is released from the dosage form and becomes available in the gastrointestinal lumen.
  2. Intestinal transit: drug moves through different gastrointestinal regions.
  3. Permeation: dissolved drug crosses the intestinal epithelium.
  4. Intestinal metabolism: enzymes in the gut wall can metabolize drug before it reaches portal blood.
  5. Transport: uptake and efflux transporters can alter intestinal and hepatic drug concentrations.
  6. Portal delivery: surviving drug enters the portal circulation.
  7. Hepatic extraction: the liver may remove a fraction of the incoming drug through metabolism, biliary excretion, or other processes.
  8. Systemic entry: drug that survives these presystemic processes enters the systemic circulation.

A simplified representation is:

$$ \text{Dose}\rightarrow\text{GI processes}\rightarrow\text{intestinal wall}\rightarrow\text{portal vein}\rightarrow\text{liver}\rightarrow\text{systemic circulation} $$

Because each step can affect the amount reaching systemic circulation, a PBPK model can represent first-pass behavior as an emergent property of several physiological and drug-specific processes rather than as one empirical parameter.

03 · Bioavailability

3. First-Pass Metabolism and Oral Bioavailability

Bioavailability, commonly denoted \(F\), is the fraction of an administered dose that reaches the systemic circulation as the parent drug. For an oral dose, it can be useful to conceptually separate the processes that determine this fraction.

A commonly used framework is:

$$ F=F_aF_gF_h $$

where:

  • \(F_a\) = fraction of the administered dose absorbed across the gut wall.
  • \(F_g\) = fraction escaping intestinal first-pass metabolism.
  • \(F_h\) = fraction escaping hepatic first-pass extraction.

This decomposition is particularly useful in PBPK because each term can be related to different physiological and mechanistic processes.

ComponentConceptual questionPotential determinants
\(F_a\) How much drug crosses the intestinal wall? Solubility, dissolution, permeability, intestinal transit, formulation, pH
\(F_g\) How much absorbed drug escapes intestinal metabolism? Gut-wall enzymes, transporters, enterocyte concentrations, residence time
\(F_h\) How much portal drug escapes the liver? Hepatic blood flow, intrinsic clearance, protein binding, uptake, metabolism, biliary processes
Important distinction: \(F_a\), \(F_g\), and \(F_h\) describe different biological processes. A low oral bioavailability does not by itself identify which process is responsible.
04 · The gut wall

4. Intestinal First-Pass Metabolism

The intestinal wall can contribute substantially to presystemic drug loss. After drug crosses the intestinal lumen-facing membrane, it encounters enterocytes containing metabolic enzymes and transport proteins.

For some drugs, intestinal cytochrome P450 enzymes—particularly CYP3A enzymes—can contribute to metabolism. Other enzymes and transporters can also be important depending on the drug.

In a PBPK model, intestinal metabolism can be represented using region-specific physiology and enzyme or transporter parameters. The model can account for the fact that different gastrointestinal segments differ in surface area, blood flow, enzyme abundance, transporter expression, and residence time.

GI lumen permeation Enterocyte uptake metabolism efflux basolateral exit portal blood Liver hepatic extraction Drug can be lost through intestinal metabolism before reaching portal blood.

A mechanistic gut model can distinguish luminal processes, enterocyte permeability, transport, and intestinal metabolism rather than representing all presystemic loss as hepatic clearance.

05 · The liver

5. Hepatic First-Pass Extraction

The liver receives blood from the portal vein and hepatic artery. Following an oral dose, absorbed drug delivered through the portal vein may therefore undergo hepatic extraction before entering systemic circulation.

Hepatic extraction is influenced by at least three broad factors:

  • Hepatic blood flow: determines how rapidly drug is delivered to the liver.
  • Unbound drug concentration: only the fraction available to the relevant hepatic processes may contribute directly to metabolic extraction.
  • Intrinsic hepatic clearance: reflects the capacity of enzymes, transporters, and other processes to remove drug when considered independently of blood-flow limitations.

These factors interact. Consequently, intrinsic clearance and observed hepatic clearance are not interchangeable quantities.

PBPK perspective: hepatic first-pass extraction emerges from the interaction between drug-specific clearance mechanisms and physiological properties such as liver blood flow and tissue composition.
06 · Hepatic model

6. The Well-Stirred Liver Model

A commonly used mechanistic framework for hepatic clearance is the well-stirred liver model. In one common form, hepatic clearance is expressed as:

$$ CL_H=\frac{Q_Hf_uCL_{int}}{Q_H+f_uCL_{int}} $$

where:

  • \(CL_H\) = hepatic clearance.
  • \(Q_H\) = hepatic blood flow.
  • \(f_u\) = fraction of drug unbound in blood or plasma, depending on the model convention.
  • \(CL_{int}\) = intrinsic hepatic clearance.

The corresponding hepatic extraction ratio is:

$$ E_H=\frac{CL_H}{Q_H} $$

and the fraction escaping hepatic extraction can be written as:

$$ F_h=1-E_H $$

Substituting the well-stirred expression gives:

$$ F_h=\frac{Q_H}{Q_H+f_uCL_{int}} $$

This equation provides a useful conceptual bridge between physiological blood flow, drug binding, and intrinsic metabolic capacity.

07 · Extraction regimes

7. Low- and High-Extraction Drugs

The relative magnitude of \(f_uCL_{int}\) compared with hepatic blood flow helps determine how hepatic extraction behaves.

Low-extraction behavior

If:

$$ f_uCL_{int}\ll Q_H $$

then the denominator of the well-stirred equation is dominated by \(Q_H\), giving approximately:

$$ CL_H\approx f_uCL_{int} $$

In this regime, hepatic clearance is strongly influenced by unbound fraction and intrinsic clearance.

High-extraction behavior

If:

$$ f_uCL_{int}\gg Q_H $$

then:

$$ CL_H\approx Q_H $$

Thus, hepatic clearance approaches the available hepatic blood flow. Increasing intrinsic metabolic capacity further may have relatively little effect once extraction is already close to flow limitation.

RegimeApproximationImportant determinants
Low extraction \(CL_H\approx f_uCL_{int}\) Unbound fraction and intrinsic clearance
Intermediate extraction Full well-stirred relationship Blood flow, binding, intrinsic clearance
High extraction \(CL_H\approx Q_H\) Hepatic blood flow
08 · Enzyme capacity

8. What Is Intrinsic Clearance?

Intrinsic clearance, \(CL_{int}\), represents the hypothetical ability of the relevant hepatic processes to remove drug independently of the limitations imposed by hepatic blood flow.

For metabolic pathways, intrinsic clearance can be related to enzyme abundance and catalytic properties. A simplified conceptual relationship is:

$$ CL_{int}\propto E_{\text{enzyme}}\times\text{catalytic capacity} $$

In a more detailed PBPK model, multiple pathways may contribute:

$$ CL_{int,total}=CL_{int,1}+CL_{int,2}+\cdots+CL_{int,n} $$

For example, a drug may be metabolized by several CYP enzymes, conjugation pathways, or other metabolic systems. The model can represent these pathways separately when sufficient information is available.

Because \(CL_{int}\) is mechanistically upstream of systemic clearance, changes in enzyme abundance or activity can propagate through the hepatic model and ultimately affect systemic exposure.

09 · Enzyme expression

9. Enzyme Abundance and First-Pass Metabolism

PBPK models can represent enzyme abundance in specific tissues rather than assuming that all metabolic capacity is located in a single abstract compartment.

For the intestine, this means that enterocyte enzyme expression can contribute to \(F_g\). For the liver, hepatic enzyme abundance contributes to \(CL_{int}\) and therefore to \(F_h\).

LocationRolePotential model consequence
Intestinal wall Presystemic metabolism of absorbed drug Reduction in \(F_g\)
Liver Metabolism of portal and systemic drug Reduction in \(F_h\) and systemic clearance
Other tissues Extrahepatic metabolism where relevant Contribution to systemic elimination

This tissue-specific representation is one of the important differences between a mechanistic PBPK model and a model that simply estimates a single empirical oral bioavailability parameter.

10 · Transport

10. Transporters Can Change First-Pass Exposure

Metabolism does not occur independently of drug transport. Uptake and efflux transporters can alter the concentration of drug available to enzymes in enterocytes and hepatocytes.

For example, an intestinal efflux transporter can return drug from enterocytes to the intestinal lumen, reducing the amount that reaches portal blood. Conversely, uptake processes can increase intracellular concentrations and potentially increase access to metabolic pathways.

A simplified conceptual sequence is:

$$ \text{luminal drug} \rightleftharpoons \text{enterocyte} \rightarrow \text{portal blood} \rightarrow \text{hepatocyte} \rightarrow \text{systemic blood} $$

Transporter-mediated movement and metabolism can therefore interact. A change in transporter activity may alter intracellular concentrations and consequently change apparent metabolic extraction.

Modeling principle: when transporter effects are important, changing an enzyme parameter alone may not reproduce the observed change in exposure. Transport and metabolism may need to be represented together.
11 · Two different processes

11. First-Pass Metabolism Versus Systemic Clearance

First-pass metabolism and systemic clearance are related but distinct.

First-pass metabolism removes drug before it reaches the systemic circulation after an extravascular dose. Systemic clearance describes elimination from the systemic circulation after drug has entered the blood.

ConceptWhen it occursEffect on oral exposure
Intestinal first-pass metabolism Before portal entry Reduces \(F_g\)
Hepatic first-pass extraction During initial portal passage through liver Reduces \(F_h\)
Systemic hepatic clearance After systemic drug reaches liver Controls ongoing elimination
Renal clearance After systemic entry Contributes to systemic elimination

This distinction is particularly important when interpreting oral versus IV studies. An IV dose bypasses intestinal first-pass metabolism and the initial gastrointestinal absorption process, while an oral dose does not.

12 · IV versus oral

12. Why IV and Oral Dosing Are Informative Together

Comparing IV and oral administration can help separate systemic disposition from presystemic processes.

For an IV dose under linear conditions:

$$ AUC_{IV}=\frac{D_{IV}}{CL} $$

For an oral dose:

$$ AUC_{oral}=\frac{F D_{oral}}{CL} $$

Therefore, when the doses are appropriately normalized and the PK is linear:

$$ F\approx \frac{AUC_{oral}/D_{oral}} {AUC_{IV}/D_{IV}} $$

This provides an estimate of absolute oral bioavailability. However, the total value of \(F\) does not by itself identify whether loss occurred during absorption, intestinal metabolism, or hepatic first pass.

PBPK advantage: mechanistic modeling can use additional information—such as permeability, enzyme abundance, transporter activity, hepatic blood flow, and tissue concentrations—to attempt to explain the components of overall bioavailability.
13 · PBPK implementation

13. How Is First-Pass Metabolism Represented in a PBPK Model?

A PBPK model represents the body using physiologically meaningful compartments or tissues. The gastrointestinal tract and liver can therefore be represented explicitly.

A simplified oral PBPK structure might contain:

  • GI lumen compartments.
  • Intestinal tissue or enterocyte compartments.
  • Portal venous blood.
  • Liver tissue.
  • Hepatic arterial and venous blood flows.
  • Systemic circulation.
  • Additional organs and tissues needed to describe distribution and elimination.

Drug movement between these components is governed by differential equations and physiological flows.

$$ \frac{dA_{\text{liver}}}{dt} = \text{hepatic input} - \text{hepatic output} - \text{metabolic loss} - \text{other elimination} $$

The precise equations depend on the chosen PBPK formulation, including assumptions about perfusion, permeability, binding, uptake, metabolism, and intracellular distribution.

14 · Mass balance

14. First-Pass Metabolism as a Mass-Balance Problem

One of the most useful ways to understand PBPK is through mass balance. Drug entering a tissue must either remain in the tissue, leave the tissue, or be eliminated through a represented pathway.

For a simplified liver model:

$$ \frac{dA_H}{dt} = Q_HC_{in} - Q_HC_{out} - R_{met} - R_{bile} $$

where \(A_H\) is the amount of drug in the liver, \(C_{in}\) and \(C_{out}\) represent relevant incoming and outgoing blood concentrations, and \(R_{met}\) and \(R_{bile}\) represent metabolic and biliary removal rates.

At steady state or under appropriate quasi-steady assumptions, the relationship between incoming drug, hepatic extraction, and outgoing drug can be simplified into clearance and extraction expressions.

This mass-balance perspective is valuable because it shows that hepatic extraction is not an isolated statistical parameter. It is the consequence of drug delivery, tissue concentrations, binding, transport, and elimination processes represented in the model.

15 · Worked example

15. Worked Example: Separating Intestinal and Hepatic First Pass

Consider a hypothetical oral drug with the following assumed characteristics:

  • Fraction absorbed across the intestinal wall: \(F_a=0.80\).
  • Fraction escaping intestinal metabolism: \(F_g=0.75\).
  • Fraction escaping hepatic first-pass extraction: \(F_h=0.50\).
  • Oral dose: \(D=200\) mg.

Step 1: Calculate oral bioavailability

Using:

$$ F=F_aF_gF_h $$

we obtain:

$$ F=(0.80)(0.75)(0.50)=0.30 $$

Thus, the model predicts an overall parent-drug bioavailability of 30%.

Step 2: Calculate the amount reaching portal blood

The amount absorbed across the intestinal wall is:

$$ D_{\text{absorbed}}=200(0.80)=160\text{ mg} $$

The amount surviving intestinal first-pass metabolism is:

$$ D_{\text{portal}}=160(0.75)=120\text{ mg} $$

Step 3: Calculate the amount surviving hepatic first pass

$$ D_{\text{systemic}}=120(0.50)=60\text{ mg} $$

So the model predicts that 60 mg of the original 200 mg oral dose reaches the systemic circulation as parent drug.

Step 4: Identify where the presystemic loss occurred

StageAmount remainingFraction retained at stage
Administered dose200 mg100%
After intestinal absorption160 mg80%
After intestinal first pass120 mg60% of dose
After hepatic first pass60 mg30% of dose
Interpretation: the overall 30% bioavailability is produced by several processes. A PBPK model can represent these processes separately, allowing the analyst to investigate which physiological or drug-specific mechanisms contribute to systemic exposure.
16 · Sensitivity

16. What Happens When First-Pass Parameters Change?

One reason PBPK models are useful is that they can simulate how changes in physiological or drug-specific parameters propagate through the system.

Suppose the previous example has \(F_a=0.80\) and \(F_g=0.75\), but hepatic escape changes from \(F_h=0.50\) to \(F_h=0.25\).

$$ F=(0.80)(0.75)(0.25)=0.15 $$

The predicted oral bioavailability falls from 30% to 15%.

In a mechanistic model, this change could arise from an increase in hepatic intrinsic clearance, a change in unbound fraction, a reduction in hepatic blood flow depending on the extraction regime, or another model parameter affecting hepatic extraction.

The important point is that the same observed change in oral exposure can potentially arise through different mechanisms.

Parameter changedPotential mechanistic consequence
Intestinal enzyme abundance ↑Greater intestinal metabolism; lower \(F_g\)
Hepatic enzyme abundance ↑Greater intrinsic clearance; potentially lower \(F_h\)
Hepatic blood flow ↓Can alter extraction, particularly for high-extraction drugs
Unbound fraction ↑Can alter hepatic availability and intrinsic-clearance contribution
Transporter activity changesCan alter tissue concentrations and access to metabolic pathways
17 · Drug interactions

17. First-Pass Metabolism and Drug–Drug Interactions

First-pass metabolism is particularly important in the context of drug–drug interactions (DDIs). An inhibitor or inducer can alter the metabolic capacity of the intestine or liver, potentially changing systemic exposure to a victim drug.

For example, inhibition of an intestinal metabolic pathway can increase the fraction escaping gut-wall metabolism:

$$ F_g\uparrow \quad\Longrightarrow\quad F_{oral}\uparrow $$

Similarly, inhibition of hepatic metabolism can increase hepatic escape for a drug whose hepatic extraction is sensitive to intrinsic clearance.

However, the magnitude and direction of the exposure change depend on the drug's extraction characteristics, binding, transport, enzyme pathways, and the site at which the interaction occurs.

Why PBPK helps: a mechanistic DDI simulation can distinguish intestinal and hepatic effects and propagate changes in enzyme or transporter activity through the physiological model rather than applying one generic exposure multiplier.
18 · Mechanistic inhibition

18. Enzyme Inhibition in a PBPK Model

Suppose an inhibitor reduces the activity of an enzyme responsible for part of a drug's intrinsic clearance. A simplified representation is:

$$ CL_{int,\text{affected}} = CL_{int,\text{baseline}}\times f_{\text{remaining}} $$

where \(f_{\text{remaining}}\) is the fraction of baseline enzyme activity remaining under the modeled inhibition condition.

If the affected pathway contributes substantially to total intrinsic clearance, the reduction can propagate into hepatic extraction:

$$ CL_{int}\downarrow \quad\Longrightarrow\quad CL_H\downarrow \quad\Longrightarrow\quad F_h\uparrow $$

The actual response depends on the extraction regime. For a high-extraction drug, reducing intrinsic clearance may have a different effect on hepatic escape than it would for a low-extraction drug.

For this reason, a PBPK model can provide a mechanistic framework for asking not merely whether exposure changes, but why it changes.

19 · Food and formulation

19. Food, Formulation, and First-Pass Processes

Food and formulation changes can influence several processes upstream of first-pass metabolism.

For example, food may alter:

  • Gastric emptying and intestinal transit.
  • Gastrointestinal fluid volume.
  • Drug dissolution.
  • Solubility and precipitation behavior.
  • Intestinal concentrations.
  • Availability of drug for absorption.

These changes can affect \(F_a\), but they can also change the amount and timing of drug presented to intestinal enzymes and transporters. Therefore, an observed food effect on oral exposure does not necessarily imply a direct change in metabolic activity.

PBPK models can incorporate physiological changes associated with fed and fasted conditions to explore how multiple mechanisms contribute to the final concentration-time profile.

20 · Route matters

20. Why Route of Administration Matters

First-pass metabolism is strongly dependent on the route of administration.

RouteTypical presystemic considerations
Oral GI dissolution, absorption, intestinal metabolism, portal delivery, hepatic first pass
IV Bypasses GI absorption and first-pass extraction before systemic entry
Intramuscular / subcutaneous Absorption from injection site; generally bypasses intestinal first pass
Transdermal Absorption through skin; generally bypasses intestinal first pass
Buccal / sublingual Can reduce or bypass some gastrointestinal and hepatic first-pass processes depending on the fraction absorbed through oral mucosa

The route therefore determines which physiological barriers and metabolic organs a drug encounters before reaching systemic circulation.

21 · What PBPK can predict

21. What Can a PBPK Model Tell Us About First Pass?

Once a PBPK model has been developed and evaluated, it can be used to explore questions such as:

  • How much of an oral dose is absorbed?
  • How much drug is lost through intestinal metabolism?
  • How much is extracted during the first hepatic passage?
  • Which enzymes contribute most strongly to presystemic metabolism?
  • How could enzyme inhibition alter oral exposure?
  • How could transporter changes alter intestinal or hepatic extraction?
  • How might changes in hepatic blood flow affect high-extraction drugs?
  • How might disease-related physiological changes alter first-pass exposure?
  • How might different formulations change the concentration presented to intestinal or hepatic pathways?

These predictions are model-based. Their reliability depends on the quality of the physiological assumptions, drug-specific parameters, and model evaluation.

22 · Interpretation

22. What First-Pass PBPK Models Do Not Tell Us Automatically

Mechanistic detail does not eliminate uncertainty. A PBPK model can contain many biological components while still depending on assumptions and estimated parameters.

  • A low predicted bioavailability does not automatically identify a single mechanism. Several processes may contribute simultaneously.
  • Enzyme abundance is not identical to metabolic clearance. Catalytic activity, binding, access to the enzyme, and transport can also matter.
  • In vitro measurements require translation. Experimental enzyme or transporter data must be scaled appropriately to the in vivo system.
  • Blood-flow assumptions matter. Hepatic extraction depends on physiological delivery as well as intrinsic metabolic capacity.
  • Parameter uncertainty propagates. Uncertainty in permeability, binding, enzyme abundance, or clearance can affect predicted exposure.
  • Model identifiability can be limited. Multiple parameter combinations can sometimes produce similar concentration-time profiles.
  • Model complexity does not guarantee predictive accuracy. Additional mechanisms should be supported by data and appropriate physiological justification.
Modeling principle: a PBPK model should provide a biologically coherent explanation of observed behavior while making its assumptions, parameters, and uncertainty explicit.
23 · Practical workflow

23. A Practical Workflow for Modeling First-Pass Metabolism

  1. Define the route and scientific question. Determine whether the objective concerns absolute bioavailability, oral exposure, metabolism, DDI, formulation, or another question.
  2. Characterize the drug. Assemble information on molecular properties, ionization, lipophilicity, solubility, permeability, protein binding, and relevant metabolic pathways.
  3. Characterize intestinal processes. Consider dissolution, transit, permeability, transporters, and intestinal enzyme abundance.
  4. Characterize hepatic processes. Specify hepatic blood flow, binding, uptake where relevant, intrinsic clearance, metabolic pathways, and biliary processes.
  5. Construct the PBPK model. Connect the GI, portal, hepatic, and systemic compartments using physiological flows and mass-balance equations.
  6. Estimate or scale drug-specific parameters. Translate experimental measurements into parameters appropriate for the physiological model.
  7. Evaluate IV disposition where available. IV data can help characterize systemic clearance and distribution independently of oral absorption and first-pass processes.
  8. Evaluate oral data. Compare predicted and observed concentration-time profiles and exposure measures.
  9. Perform sensitivity analysis. Identify which parameters have the greatest influence on oral exposure and first-pass extraction.
  10. Evaluate uncertainty. Determine how uncertainty in key parameters propagates into predictions.
  11. Use the model for simulation. Apply the evaluated model to relevant scenarios such as DDIs, formulation changes, physiological differences, or alternative dosing conditions.
24 · Putting it together

24. The Complete First-Pass Picture

The central PBPK concept is that oral exposure is the result of a chain of physiological and drug-specific processes rather than a single empirical bioavailability parameter.

$$ F_{\text{oral}} = F_aF_gF_h $$

where \(F_a\) describes absorption, \(F_g\) describes escape from intestinal first-pass metabolism, and \(F_h\) describes escape from hepatic first-pass extraction.

At the hepatic level, the well-stirred relationship provides one important bridge between physiology and drug-specific clearance:

$$ CL_H= \frac{Q_Hf_uCL_{int}} {Q_H+f_uCL_{int}} $$

These relationships connect several levels of description:

Drug properties permeability · binding · enzymes Physiology blood flow · tissues · transit PBPK model First pass intestinal + hepatic Systemic exposure C(t) · AUC · Cmax PD Mechanistic assumptions are propagated through the model to predict systemic drug exposure.

PBPK connects drug-specific properties and physiology to presystemic extraction and ultimately to systemic concentration and exposure.

25. Key Takeaways

  • First-pass metabolism is the presystemic metabolism of drug before it reaches the systemic circulation.
  • For oral administration, important presystemic sites include the intestinal wall and liver.
  • Oral bioavailability can be conceptually decomposed as \(F=F_aF_gF_h\).
  • \(F_a\) describes the fraction absorbed, \(F_g\) the fraction escaping intestinal metabolism, and \(F_h\) the fraction escaping hepatic extraction.
  • Intestinal metabolism can be an important determinant of oral exposure and should not automatically be attributed to hepatic clearance.
  • Hepatic first-pass extraction depends on hepatic blood flow, unbound drug, and intrinsic clearance, among other mechanisms.
  • The well-stirred liver model provides a useful relationship between hepatic blood flow and intrinsic clearance.
  • Low-extraction and high-extraction drugs can respond differently to changes in intrinsic clearance, protein binding, and hepatic blood flow.
  • Transporters can modify intracellular drug concentrations and therefore interact with metabolic pathways.
  • IV and oral dosing provide complementary information because IV administration bypasses gastrointestinal absorption and intestinal first-pass processes.
  • A PBPK model can represent first-pass metabolism mechanistically rather than treating oral bioavailability as an unexplained fixed parameter.
  • Drug–drug interactions can alter intestinal or hepatic first-pass metabolism through changes in enzyme or transporter activity.
  • Food and formulation effects can change absorption and the concentration of drug presented to intestinal and hepatic pathways.
  • Mechanistic detail does not eliminate uncertainty: model predictions remain conditional on parameter values, physiological assumptions, and model structure.
  • The scientific value of first-pass PBPK modeling comes from connecting observable exposure to plausible underlying physiological mechanisms.
Next step

Where to Go Next

A natural progression from first-pass metabolism is to study hepatic clearance and the well-stirred liver model in greater detail, followed by hepatic blood-flow limitation, intrinsic clearance, enzyme scaling, transporter-mediated hepatic uptake, and drug–drug interaction modeling.

For the gastrointestinal side, the next useful topics are intestinal permeability, drug dissolution and solubility, mechanistic absorption models, and intestinal transit. Together, these concepts explain how a PBPK model moves from an oral dose in the GI tract to systemic drug exposure.

The broader goal is to understand how physiological parameters and drug-specific properties interact to produce the concentration-time profiles observed in clinical studies.

References

References

  1. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Wolters Kluwer.
  2. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker.
  3. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel-tube” model. Journal of Pharmacokinetics and Biopharmaceutics.
  4. Jones HM, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: Pharmacometrics & Systems Pharmacology.
  5. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using physiologically based pharmacokinetic models. Clinical Pharmacokinetics.
```

Related Tutorials

Clinical Biostats

```
← Back to Pharmacokinetics Tutorials